ADVANCING BETTER TREATMENTS FOR ALL STAGES OF PARKINSON ’ S
THE MICHAEL J . FOX FOUNDATION 2024 YEAR IN REVIEW
Approximately half of the treatments currently in clinical testing aim to reduce PD ’ s motor and non-motor symptoms .
induced involuntary movements , and Tavapadon , an oral drug from Cerevel to increase “ on ” time among people with PD , both advanced to Phase III testing . Phase II and III trials by Pharma Two B found P2B001 , a once-daily combination of extended-release pramipexole plus low-dose rasagiline , had fewer side effects and was more effective than either drug alone in people with early untreated PD . Pharma Two B is expected to submit P2B001 for FDA approval .
21